Hernan A Bazan1, Yan Lu2, Bokkyoo Jun2, Zhide Fang3, T Cooper Woods4, Song Hong5. 1. Department of Surgery, Section of Vascular/Endovascular Surgery, Ochsner Clinic and The University of Queensland, School of Medicine, 1514 Jefferson Highway, New Orleans, LA 70121, United States. Electronic address: hbazan@ochsner.org. 2. Neuroscience Center of Excellence, Louisiana State University Health Sciences Center, New Orleans, LA 70112, United States. 3. Biostatistics Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA 70112, United States. 4. Department of Physiology and the Section of Cardiology, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, 70112. 5. Neuroscience Center of Excellence, Louisiana State University Health Sciences Center, New Orleans, LA 70112, United States; Department of Ophthalmology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, United States.
Abstract
BACKGROUND: Efficient biomarkers for early prediction and diagnosis of an acutely symptomatic carotid plaque rupture event are currently lacking, impairing the ability to diagnose and treat patients with an acute plaque rupture events in a timely fashion. Resolvins are endogenous inflammation-resolving lipid mediators that are induced by inflammatory insults. We hypothesized that resolvin and other lipid profiles in sera likely mark the process towards plaque rupture. METHODS: Circulating lipids associated with plaque rupture events were quantitatively profiled via targeted mediator-lipidomics using ultraperformance liquid chromatography tandem mass spectrometry in patients with acutely symptomatic and asymptomatic carotid disease. RESULTS: Resolvin D1 (RvD1, 82 ± 11pM vs. 152 ± 17pM, p = 0.001) and docosahexaenoic acid (DHA) (0.052 ± 0.007µM versus 0.076 ± 0.008µM, p = 0.025) levels are decreased in the sera of patients presenting with an acutely symptomatic carotid plaque rupture event (n = 21) compared to patients with asymptomatic (n = 24) high-grade carotid stenosis. Circulating arachidonic acid (AA) levels, however, were higher (0.429 ± 0.046µM versus 0.257 ± 0.035µM, p < 0.01) in acutely symptomatic compared to asymptomatic carotid patients. ROC curve analysis demonstrates that the serum ratio AA:RvD1 (AUC 0.84, sensitivity 0.71, specificity 0.92) and AA:DHA (AUC 0.86, sensitivity 0.90, specificity 0.71) are biomarkers for the risk of atherosclerotic plaque rupture. CONCLUSIONS: A circulating pro-inflammatory lipid profile, characterized by high AA:RvD1 and AA:DHA, is associated with acutely symptomatic carotid disease and stroke.
BACKGROUND: Efficient biomarkers for early prediction and diagnosis of an acutely symptomatic carotid plaque rupture event are currently lacking, impairing the ability to diagnose and treat patients with an acute plaque rupture events in a timely fashion. Resolvins are endogenous inflammation-resolving lipid mediators that are induced by inflammatory insults. We hypothesized that resolvin and other lipid profiles in sera likely mark the process towards plaque rupture. METHODS: Circulating lipids associated with plaque rupture events were quantitatively profiled via targeted mediator-lipidomics using ultraperformance liquid chromatography tandem mass spectrometry in patients with acutely symptomatic and asymptomatic carotid disease. RESULTS: Resolvin D1 (RvD1, 82 ± 11pM vs. 152 ± 17pM, p = 0.001) and docosahexaenoic acid (DHA) (0.052 ± 0.007µM versus 0.076 ± 0.008µM, p = 0.025) levels are decreased in the sera of patients presenting with an acutely symptomatic carotid plaque rupture event (n = 21) compared to patients with asymptomatic (n = 24) high-grade carotid stenosis. Circulating arachidonic acid (AA) levels, however, were higher (0.429 ± 0.046µM versus 0.257 ± 0.035µM, p < 0.01) in acutely symptomatic compared to asymptomatic carotidpatients. ROC curve analysis demonstrates that the serum ratio AA:RvD1 (AUC 0.84, sensitivity 0.71, specificity 0.92) and AA:DHA (AUC 0.86, sensitivity 0.90, specificity 0.71) are biomarkers for the risk of atherosclerotic plaque rupture. CONCLUSIONS: A circulating pro-inflammatory lipid profile, characterized by high AA:RvD1 and AA:DHA, is associated with acutely symptomatic carotid disease and stroke.
Authors: Song Hong; Haibin Tian; Yan Lu; James Monroe Laborde; Filipe A Muhale; Quansheng Wang; Bhagwat V Alapure; Charles N Serhan; Nicolas G Bazan Journal: Am J Physiol Cell Physiol Date: 2014-10-01 Impact factor: 4.249
Authors: Erik S Musiek; Jin K Cha; Huiyong Yin; William E Zackert; Erin S Terry; Ned A Porter; Thomas J Montine; Jason D Morrow Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2004-01-05 Impact factor: 3.205
Authors: Song Hong; Timothy F Porter; Yan Lu; Sungwhan F Oh; Padmini S Pillai; Charles N Serhan Journal: J Immunol Date: 2008-03-01 Impact factor: 5.422
Authors: Hernan A Bazan; Samuel A Hatfield; Chasity B O'Malley; Ashton J Brooks; Daniel Lightell; T Cooper Woods Journal: Stroke Date: 2015-10-08 Impact factor: 7.914
Authors: Joanna M Poczobutt; Miguel Gijon; Jay Amin; Dwight Hanson; Howard Li; Deandra Walker; Mary Weiser-Evans; Xian Lu; Robert C Murphy; Raphael A Nemenoff Journal: PLoS One Date: 2013-11-11 Impact factor: 3.240
Authors: April S Caravaca; Alessandro L Gallina; Laura Tarnawski; Vladimir S Shavva; Romain A Colas; Jesmond Dalli; Stephen G Malin; Henrik Hult; Hildur Arnardottir; Peder S Olofsson Journal: Proc Natl Acad Sci U S A Date: 2022-05-27 Impact factor: 12.779
Authors: Hildur Arnardottir; Silke Thul; Sven-Christian Pawelzik; Glykeria Karadimou; Gonzalo Artiach; Alessandro L Gallina; Victoria Mysdotter; Miguel Carracedo; Laura Tarnawski; April S Caravaca; Roland Baumgartner; Daniel Fj Ketelhuth; Peder S Olofsson; Gabrielle Paulsson-Berne; Göran K Hansson; Magnus Bäck Journal: J Clin Invest Date: 2021-12-15 Impact factor: 14.808
Authors: Jun-Sub Jung; A Ra Kho; Song Hee Lee; Bo Young Choi; Shin-Hae Kang; Jae-Young Koh; Sang Won Suh; Dong-Keun Song Journal: Korean J Physiol Pharmacol Date: 2020-02-20 Impact factor: 2.016